华蟾素胶囊联合化疗治疗晚期非小细胞肺癌的临床效果及安全性  

Clinical effect and safety of Cinobufacini Capsules combined with chemotherapy in the treatment of advanced non-small cell lung cancer

作　　者：余婷婷[1] 陈飞[1] 程丹[1] 李俊[1] YU Ting-ting;CHEN Fei;CHENG Dan;LI Jun(The Second Department of Oncology,Xiaogan Hospital Affiliated to Wuhan University of Science and Technology, Hubei Province,Xiaogan 432000,China)

机构地区：[1]武汉科技大学附属孝感医院肿瘤二科,湖北孝感432000

出　　处：《中国当代医药》2018年第35期53-55,共3页China Modern Medicine

摘　　要：目的观察华蟾素胶囊联合化疗对晚期非小细胞肺癌的临床效果及安全性。方法选取我科2015年7月～2016年7月收治的63例晚期非小细胞肺癌患者作为研究对象,随机分为实验组(33例)和对照组(30例)。实验组采取常规化疗方案加用华蟾素胶囊,对照组使用常规化疗方案。观察两组的近期疗效、不良反应发生情况及肿瘤标志物变化情况。结果实验组治疗后的近期疗效明显优于对照组,差异有统计学意义(P<0.05)。实验组的骨髓抑制情况明显低于对照组,差异有统计学意义(P<0.05)。两组的胃肠道反应发生率比较,差异无统计学意义(P>0.05)。实验组治疗后的肿瘤标志物CEA水平较治疗前明显降低,差异有统计学意义(P<0.05)。对照组治疗前后的肿瘤标志物CEA水平比较,差异无统计学意义(P>0.05)。实验组治疗后的CEA水平明显低于对照组,差异有统计学意义(P<0.05)。结论华蟾素胶囊联合化疗可以提高晚期非小细胞肺癌的临床疗效并减轻毒副作用。Objective To observe the clinical effect and safety of Cinobufacini Capsules combined with chemotherapy in the treatment of advanced non-small cell lung cancer(NSCLC). Methods A total of 63 patients with advanced NSCLC admitted to our department from July 2015 to July 2016 were selected and randomly divided into the experimental group(n=33) and the control group(n=30). In the experimental group, conventional chemotherapy plus Cinobufacini Capsules was used, while in the control group, conventional chemotherapy alone was adopted. The short-term efficacy,occurrence of adverse reactions and changes of tumor markers were observed in the two groups. Results The short-term efficacy of the experimental group after treatment was significantly better than that of the control group, with significant difference(P<0.05). The bone marrow suppression of the experimental group was much lower compared with that in the control group, with significant difference(P<0.05). There was no significant difference in gastrointestinal reactions between the two groups(P>0.05). The tumor marker carcino-embryonic antigen(CEA) in the experimental group was significantly lower than that before treatment, and the difference was statistically significant(P<0.05). In the control group,there was no great difference in the tumor marker CEA after and before treatment(P>0.05). The level of CEA in the experimental group after treatment was significantly lower than that in the control group, with significant difference(P<0.05). Conclusion Cinobufacini Capsules combined with chemotherapy can improve the clinical efficacy and reduce side effects of advanced NSCLC.

关 键 词：华蟾素胶囊 非小细胞肺癌 临床疗效 安全性 

分 类 号：R734.2[医药卫生—肿瘤]